ClinicalTrials.gg

Program

alisertib

Also written as “Alisertib”, “[^14C]-alisertib” and “Alisertib (MLN8237)”.

Its studies are mostly in Lymphoma · Small Cell Lung Carcinoma · Breast Neoplasms · Ovarian Neoplasms · Lymphoma, Large B-Cell, Diffuse, led by 3 companies.

Furthest: phase 3, since Nov 28, 201124 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda200 open or runningphase 3since Nov 28, 2011Jul 12, 2007none ahead
Puma Biotechnology33 open or runningphase 2since Sep 27, 2023Sep 27, 2023Oct 30, 2027phase 2 · NCT06095505
Sarah Cannon Research Institute10 open or runningphase 2since Jul 6, 2014Jul 6, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Jul 12, 2007.

  1. Nov 28, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralTakeda · NCT01482962 · 271 enrolled · United States, Australia, Austria and more
  2. Jan 13, 2012Phase 1 study in LymphomaTakeda · NCT01512758 · 36 enrolled · Singapore
  3. Jun 1, 2012Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT01613261 · United States
  4. Oct 17, 2012Phase 1 study in LymphomaTakeda · NCT01714947 · 3 enrolled · United States
  5. Apr 29, 2013Phase 1 study in LymphomaTakeda · NCT01844583 · 55 enrolled · United States
  6. Jul 1, 2013Phase 1 study in LymphomaTakeda · NCT01898078 · 26 enrolled · United States
  7. Dec 4, 2013Phase 2 study in Small Cell Lung CarcinomaTakeda · NCT02038647 · 178 enrolled · United States, Belgium, Canada and more
  8. Jul 6, 2014Sarah Cannon Research Institute's first study: phase 2 study in Breast NeoplasmsNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT02187991 · 169 enrolled · United States
  9. Jul 30, 2014Phase 1 study in LymphomaTakeda · NCT02214147 · 36 enrolled · United States
  10. Oct 3, 2014Phase 1 study in LymphomaTakeda · NCT02259010 · 24 enrolled · United States
  11. Feb 11, 2015Phase 1 study in Ovarian NeoplasmsTakeda · NCT02367352 · 9 enrolled · Japan, Korea, Republic of
  12. Sep 27, 2023Puma Biotechnology's first study: phase 2 study in Small Cell Lung CarcinomaNew to Puma BiotechnologyPuma Biotechnology · NCT06095505 · 120 planned · United States
  13. Apr 12, 2024Phase 2 study in Breast NeoplasmsPuma Biotechnology · NCT06369285 · 225 planned · United States, Portugal, Spain
  14. Mar 6, 2026Phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT07465757 · 50 planned · United States, France, Spain

Ahead

  1. Oct 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT06095505
  2. Dec 30, 2027Primary completion: phase 2 study in Breast NeoplasmsPuma Biotechnology · NCT06369285
  3. Mar 31, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaPuma Biotechnology · NCT07465757

TargetBeta

AURKA →read by rule
“Serine/threonine-protein kinase Aurora-A inhibitor”ChEMBL 37, by rule

Studies

All 24 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07465757Small Cell Lung Carcinoma · United States, France, Spain2RecruitingPuma BiotechnologyMar 31, 202850
NCT06369285Breast Neoplasms · United States, Portugal, Spain2RecruitingPuma BiotechnologyDec 30, 2027225
NCT06095505Small Cell Lung Carcinoma · United States2RecruitingPuma BiotechnologyOct 30, 2027120
NCT02367352Ovarian Neoplasms · Japan, Korea, Republic of1TerminatedTakedaMay 23, 20179
NCT02259010Lymphoma · United States1CompletedTakedaMar 27, 201524
NCT02214147Lymphoma · United States1CompletedTakedaApr 5, 201636
NCT02187991Breast Neoplasms · United States2CompletedSarah Cannon Research InstituteApr 11, 2024169
NCT02038647Small Cell Lung Carcinoma · United States, Belgium, Canada and more2CompletedTakedaJan 3, 2016178
NCT01898078Lymphoma · United States1CompletedTakedaMar 5, 201426
NCT01844583Lymphoma · United States1CompletedTakedaAug 4, 201455
NCT01714947Lymphoma · United States1CompletedTakedaApr 4, 20133
NCT01613261Advanced Nonhematologic Malignancies · United States1WithdrawnTakedaSep 20150
NCT01512758Lymphoma · Singapore1CompletedTakedaOct 8, 201336
NCT01482962Lymphoma, T-Cell, Peripheral · United States, Australia, Austria and more3CompletedTakedaJun 30, 2015271
NCT01397825Lymphoma, Large B-Cell, Diffuse · United States, Italy, Spain and more2CompletedTakedaFeb 5, 201545
NCT01094288Advanced Solid Tumors · United States1CompletedTakedaFeb 28, 201441
NCT01045421Carcinoma, Non-Small-Cell Lung · United States2CompletedTakedaMay 2013273
NCT00962091Advanced Solid Tumors · United States1CompletedTakedaDec 28, 201153
NCT00853307Ovarian Neoplasms · United States2CompletedTakedaNov 23, 200931
NCT00830518Leukemia, Myeloid, Acute · United States2CompletedTakedaFeb 2, 201057
NCT00807495Lymphoma, Large B-Cell, Diffuse · United States2CompletedTakedaJan 4, 201148
NCT00697346Lymphoma, B-Cell, Marginal Zone · United States1CompletedTakedaOct 1, 201658
NCT00651664Advanced Malignancies · Spain1CompletedTakedaSep 1, 201059
NCT00500903Advanced Malignancies · United States1CompletedTakedaAug 1, 201087

How it is read

Names in the registry

  • “Alisertib”, 23 entries
  • “alisertib”, 2 entries
  • “[^14C]-alisertib”, 1 entry
  • “Alisertib (MLN8237)”, 1 entry
  • “MLN8237 (Alisertib)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.